Recent Company News

• 04:09 AM ET Oct 08, 2026
  

  Biohaven, Ono Pharmaceutical enter into exclusive license agreement for Biohaven's IgG degrader portfolio in Japan, South Korea, Taiwan, ASEAN countries ($11.88, 0.00)

• 09:57 AM ET Sep 28, 2026
  

  StreetAccount Summary - Private company transactions for the week ended 26-Sep

• 02:01 PM ET Sep 21, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 14-Sep

• 01:39 AM ET Sep 16, 2026
  

  Japan approves marketing of Ono Pharmaceutical's XCOPRI for partial-onset seizures

• 12:32 AM ET Sep 14, 2026
  

  Antengene reports a preclinical research Paper on CD73 Small Molecule Inhibitor ATG-037 combined with selinexor was published in Cancer Gene Therapy (HK$3.34, 0.00)

• 09:02 PM ET Sep 01, 2026
  

  Ono Pharmaceutical enters into drug discovery partnership agreement with Aitia, Inc (¥2466.5000, -19)

• 08:09 AM ET Aug 14, 2026
  

  UK MHRA approves ROMVIMZA for adults with tenosynovial giant cell tumours (¥2430.0000, 0)

• 02:01 PM ET Aug 10, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 3-Aug

• 07:06 AM ET Aug 06, 2026
  

  Ono Pharmaceutical enters into drug discovery partnership and option agreement with Mediar Therapeutics (¥2338.0000, 0)

• 11:05 PM ET Jul 30, 2026
  

  Ono Pharmaceutical reports Q1 net income attributable ¥24.15B vs FactSet ¥16.92B [2 est, ¥15.98-17.86B] (¥2363.0000, -94.5)